Articles related to BETA-BLOCKERS

In a propensity-matched analysis of more than 66,000 adults with hypertension, blood-brain barrier (BBB)-crossing antihypertensives were associated with a 16% lower dementia risk than BBB-non-crossing agents. The observational design prevents causal conclusions but adds to growing interest in whether some antihypertensives may influence cognitive outcomes beyond blood pressure control.

Celebrity disclosures about using beta blockers for performance anxiety are prompting patient questions in primary care, reviving a decades-old off-label use with a comparatively lower risk profile than benzodiazepines.

“Use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” — FDA Class II Recall Definition

Beta-blocker use was not associated with reductions in all-cause mortality or cardiovascular mortality compared with the absence of beta-blocker therapy.

Women had a 45% higher relative risk for death, heart attack, or heart failure hospitalization when taking beta-blockers compared to non-beta-blocker groups, with the risk confined to those with preserved LVEF and higher doses.

The FDA says on its website that it has been investigating drugs for nitrosamines in some types of medications, noting they’re common in water and foods. But the agency noted that such impurities have been linked to an increase in cancer in individuals who are exposed to elevated levels and over long periods of time.